Ivermectin, best known as an antiparasitic medication, has shown several intriguing connections to diabetes through laboratory and animal research, though none have yet translated into approved treatments for humans with the disease. The drug appears to lower blood sugar and cholesterol in mice through a specific metabolic receptor, boost a key energy-sensing enzyme in liver cells, and even stimulate insulin release from pancreatic beta cells in a glucose-dependent way. These findings come from cell cultures and animal models rather than clinical trials in people with diabetes, so the connection remains firmly in the realm of early science rather than medical practice.
The FXR Pathway and Blood Sugar
The most studied link between ivermectin and diabetes-related metabolism runs through a protein called the farnesoid X receptor, or FXR. This receptor sits inside cells and acts as a master switch for genes that control how the body handles sugar and fat. Bile acids are its natural activators, but researchers screening large libraries of compounds discovered that ivermectin also binds to FXR and switches it on. When mice were treated with ivermectin, their blood glucose and cholesterol levels dropped. Crucially, these effects disappeared in mice that had been genetically engineered to lack FXR entirely, confirming that the metabolic changes were running through that specific receptor rather than some unrelated pathway.1PubMed. The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism
A follow-up study explored this mechanism further by testing several chemical relatives of ivermectin, known collectively as avermectin analogues. The analogues that were able to bind and activate FXR reduced fat accumulation in the liver, lowered serum cholesterol and glucose, and improved insulin sensitivity. Those that could not activate FXR did none of these things. The pattern held across every metabolic marker the researchers tested, reinforcing the idea that FXR activation is the critical step.2PubMed Central. Selective targeting of nuclear receptor FXR by avermectin analogues with therapeutic effects on nonalcoholic fatty liver disease
FXR is already a target of interest in metabolic disease research independent of ivermectin. It helps regulate bile acid production, and bile acids themselves influence glucose metabolism. By modulating FXR, ivermectin appears to alter bile acid profiles in the blood, creating a downstream cascade that touches sugar and fat handling at multiple points.3Journal of Analytical Science and Technology. Simultaneous determination of seven bile acids to study the effect of ivermectin on their plasma levels in rat by UHPLC–MS/MS
Activating the Body’s Energy Sensor
A separate line of evidence points to ivermectin’s effect on AMPK, an enzyme that functions as a cellular fuel gauge. When energy is low, AMPK switches on processes that generate fuel and switches off processes that consume it. This includes ramping up the breakdown of stored fat and improving how cells respond to insulin. Drugs that activate AMPK, such as metformin, are already a cornerstone of type 2 diabetes treatment.
In lab experiments using human liver cells, ivermectin boosted the active form of AMPK by roughly 133 percent compared to untreated cells. The ratio of active to total AMPK increased by about 124 percent. These are large shifts in a pathway that directly governs how liver cells process sugar and fat.4PubMed Central. Permethrin and ivermectin modulate lipid metabolism in steatosis-induced HepG2 hepatocyte The experiments were done in cells loaded with extra fat to mimic a fatty liver, which is common in people with type 2 diabetes and insulin resistance. Ivermectin appeared to help those cells manage their lipid accumulation more effectively.
Whether this AMPK activation would occur at doses safe for humans, and whether it would produce meaningful metabolic benefits, has not been tested in people. The gap between “this happens in a dish of cells” and “this helps a patient” is wide. Still, the fact that ivermectin touches the same energy-sensing pathway as one of the world’s most prescribed diabetes drugs is what makes researchers pay attention.
Insulin Secretion and the Pancreatic Clock
Perhaps the most unexpected diabetes connection involves ivermectin’s effect on the insulin-producing beta cells of the pancreas. Researchers studying how the body’s internal circadian clock influences blood sugar regulation discovered that when the clock machinery in beta cells is disrupted, those cells fail to release enough insulin in response to glucose. This is relevant because growing evidence suggests that circadian disruption, from shift work, poor sleep, or genetic variation, contributes to type 2 diabetes risk.
In a screen of thousands of small molecules looking for compounds that could rescue insulin secretion in clock-disrupted beta cells, ivermectin emerged as a hit. Testing in both mouse and human pancreatic islet cells showed that ivermectin stimulated insulin release, but only when glucose was elevated. That glucose dependence is a desirable trait because it means the drug would not push blood sugar dangerously low the way some older diabetes medications can. The researchers traced ivermectin’s effect to a specific receptor on beta cells called P2Y1, which turned out to be under circadian clock control.5PubMed Central. P2Y1 purinergic receptor identified as a diabetes target in a small-molecule screen to reverse circadian β-cell failure
This finding sits at the intersection of two active fields: circadian biology and diabetes. If future work confirms that ivermectin or a related compound can restore insulin secretion in people whose beta cells have become sluggish due to circadian disruption, it could open a new angle on treating or preventing diabetes that current medications do not address.
Immune Modulation and Autoimmune Diabetes
Type 1 diabetes is fundamentally an autoimmune disease in which the immune system attacks and destroys the pancreas’s beta cells. It is a different condition from type 2 diabetes, which centers on insulin resistance and metabolic dysfunction. But ivermectin’s immune-modulating properties have prompted some speculation about whether it could influence autoimmune processes.
In a mouse model of autoimmune brain inflammation, ivermectin shifted the balance of immune cells in a potentially useful direction. It suppressed the pro-inflammatory T cells that drive tissue damage while boosting regulatory T cells that keep the immune system in check. Specifically, it inhibited the proliferation of certain T cell subsets and reduced their secretion of inflammatory signaling molecules, while increasing the production of interleukin-2 and expanding the population of regulatory T cells.6PubMed Central. Ivermectin Protects Against Experimental Autoimmune Encephalomyelitis in Mice by Modulating the Th17/Treg Balance Involved in the IL-2/STAT5 Pathway
This immune rebalancing is interesting because the same kinds of pro-inflammatory T cells are involved in the autoimmune destruction of beta cells in type 1 diabetes. Whether ivermectin could dampen that specific autoimmune attack has not been tested directly in type 1 diabetes models, and the leap from one autoimmune model to another is speculative. The research does show that ivermectin has broader biological effects than its original antiparasitic role would suggest, but this particular thread is among the thinnest in connecting the drug to diabetes.
Diabetic Neuropathy and Nerve Repair
One of the most debilitating complications of long-standing diabetes is peripheral neuropathy, the gradual damage to nerves in the hands and feet that causes numbness, tingling, and pain. Current treatments manage symptoms but do little to repair the damaged nerves themselves. A study examining wound healing found that ivermectin promoted the regeneration of peripheral nerves in an injury model, accelerating the regrowth of nerve fibers during the healing process.7PubMed Central. Ivermectin Promotes Peripheral Nerve Regeneration during Wound Healing
The researchers noted that their findings raised the question of whether ivermectin might also help in conditions where nerve damage is more severe and persistent, explicitly naming diabetes as a candidate for future experiments. This is purely a research proposal at this stage; no one has tested whether ivermectin helps regenerate nerves damaged by chronically high blood sugar. Diabetic neuropathy involves a complex mix of metabolic stress, inflammation, and vascular damage to nerve tissue that makes it harder to treat than a clean surgical injury. But the observation that ivermectin has nerve-repair properties at all is notable because so few drugs show any meaningful ability to promote peripheral nerve regeneration.
Drug Interactions for People on Diabetes Medications
For people who take diabetes medications and also need ivermectin for a parasitic infection, drug interactions are a practical concern. Ivermectin is broken down in the liver primarily by an enzyme called CYP3A4. Anything that slows down that enzyme could cause ivermectin to accumulate to higher-than-expected levels in the body.
An in silico and laboratory study tested whether two drugs commonly prescribed alongside diabetes treatments, metformin and hydrochlorothiazide (a diuretic often used for the high blood pressure that frequently accompanies diabetes), interfere with CYP3A4’s ability to metabolize ivermectin. Metformin showed only weak inhibition of the enzyme, suggesting minimal risk of it causing ivermectin to build up. Hydrochlorothiazide, on the other hand, was a potent inhibitor of CYP3A4 in the same experiments, which means taking it alongside ivermectin could theoretically slow ivermectin’s clearance and increase the risk of side effects.8PubMed Central. The Effect of Metformin and Hydrochlorothiazide on Cytochrome P450 3A4 Metabolism of Ivermectin: Insights from In Silico Experimentation
This distinction matters because many people with type 2 diabetes take both metformin and a thiazide diuretic. The metformin appears to pose little concern, but the hydrochlorothiazide interaction is something a prescribing doctor should be aware of. That said, this was a laboratory study, not a clinical trial tracking real outcomes in patients. The actual clinical significance of this interaction in standard dosing scenarios remains to be confirmed in human studies.
What Happens in the Gut
The gut microbiome has become an area of intense interest in diabetes research, with growing evidence that the composition of bacteria in the intestines influences blood sugar regulation, inflammation, and insulin sensitivity. Because ivermectin is typically taken orally and passes through the digestive tract, researchers have investigated whether it disrupts the gut’s microbial community.
One study examining healthy adults found that ivermectin introduced only minor and temporary changes to the gut microbial community, both in terms of which species were present and what metabolic byproducts they generated. The researchers concluded that the drug is unlikely to cause meaningful dysbiosis in healthy people at standard doses.9PubMed Central. Impact of Ivermectin on the Gut Microbial Ecosystem However, the picture gets more complicated at higher doses and in animal studies. Rat experiments using avermectin at both low and high doses showed that the drug increased bacterial diversity in the colon and shifted the balance of major bacterial groups. These changes were accompanied by disruptions to the colon barrier and alterations in liver metabolism. Correlation analyses suggested that the shifts in gut bacteria were linked to metabolic changes in the liver, hinting that the microbiome may mediate some of ivermectin’s metabolic effects.10The Microbe. Ivermectin impact over gut microbiota diversity: A comprehensive and updated analysis from pre-clinical and clinical evaluations
For someone with diabetes, whose gut microbiome may already be altered by the disease itself or by medications like metformin, the question of how ivermectin affects gut bacteria is more than academic. But the evidence so far suggests that at the doses used for treating parasitic infections, the impact is modest and short-lived in otherwise healthy individuals. Whether the same holds true for people with metabolic disease is an open question.
Safety at Standard and Non-Standard Doses
Ivermectin has been used safely in hundreds of millions of people worldwide for parasitic diseases, typically as a single dose or a short course. At these standard doses, it is generally well tolerated. Side effects tend to be mild and related to the body’s inflammatory response to dying parasites rather than to the drug itself. Reported non-neurological side effects include itching, muscle pain, nausea, diarrhea, low blood pressure upon standing, and skin reactions.11PubMed Central. Identifying the Toxidrome of Ivermectin Toxicity
The safety profile becomes more concerning with higher or repeated doses, which is relevant to any discussion of repurposing ivermectin for a chronic condition like diabetes. Many of the metabolic effects described in the lab studies above were observed at concentrations that may exceed what can be safely achieved in a human body with standard dosing. This is a recurring challenge in drug repurposing: a compound might have a promising effect on cells in a dish at a certain concentration, but reaching that same concentration in a living person could require doses that carry unacceptable risks.
Ivermectin is also primarily processed by the liver, and people with diabetes frequently have some degree of fatty liver disease or liver impairment. This could alter how the drug is metabolized, potentially leading to higher-than-expected blood levels even at standard doses. Anyone with diabetes who is prescribed ivermectin for a parasitic infection should mention their full medication list to their prescriber, particularly if they take hydrochlorothiazide or other drugs known to affect liver enzymes.
Why No Clinical Trials for Diabetes Yet
Given all these laboratory findings, a reasonable question is why ivermectin has not been tested in clinical trials for diabetes. Several factors slow that process. First, the metabolic effects have been demonstrated primarily in animal models and cell cultures. Promising results at this stage fail to translate into human benefit more often than they succeed. Second, ivermectin is an old, inexpensive, off-patent drug, which means there is little commercial incentive for pharmaceutical companies to fund the large clinical trials needed for a new indication. Third, the doses required to produce metabolic effects may be higher than those currently approved for parasitic infections, and establishing the safety of chronic higher-dose ivermectin would require substantial investment in toxicology studies.
There is also the practical matter of public perception. Ivermectin became politically and culturally charged during the COVID-19 pandemic, when unproven claims about its antiviral properties led to widespread self-medication and polarized debate. That controversy has made it harder to have measured scientific conversations about the drug’s genuine biological properties, including its metabolic effects. Researchers working on ivermectin’s non-parasitic activities have noted the awkwardness of the situation, where legitimate lab findings get tangled up with misinformation and conspiracy theories in the public imagination.
None of this means the science is wrong. The FXR activation, the AMPK boost, the glucose-dependent insulin secretion, and the immune modulation are real observations published in peer-reviewed journals. What is missing is the bridge between those observations and a treatment that could help people. That bridge requires clinical trials, and those trials require funding, regulatory approval, and willing participants, all of which are harder to assemble for a generic drug that carries cultural baggage.
Ivermectin’s Antiparasitic Mechanism Is Unrelated to Its Metabolic Effects
One source of confusion worth clearing up is the assumption that ivermectin’s known effects on parasites have something to do with its potential metabolic effects. They do not. As an antiparasitic, ivermectin works by binding to glutamate-gated chloride channels found in invertebrates, paralyzing and killing the parasites. Humans do not have these channels in the same form, which is a major reason the drug is so safe for us at standard doses.12PubMed Central. Ivermectin: A Multifaceted Drug With a Potential Beyond Anti-parasitic Therapy
The metabolic effects described throughout this article involve entirely different molecular targets: FXR, AMPK, and the P2Y1 receptor on beta cells. These are mammalian pathways that have nothing to do with killing worms or mites. The fact that a single molecule can interact with such different biological targets is not unusual in pharmacology. Many drugs have “off-target” effects that are unrelated to their primary purpose, and sometimes those off-target effects turn out to be medically interesting. Aspirin was used for pain long before anyone discovered it also prevents blood clots. Minoxidil was a blood pressure drug before it became a hair-growth treatment. Ivermectin’s metabolic activity may simply be another case of a familiar drug doing unexpected things to molecular machinery it was never designed to touch.